MSME (Udyam registered) Ministry of MSME
- Category
- Micro (2021-22)
- Udyam number
- UDYAM-KR-13-0019819
Endocrine Pharma Private Limited
Endocrine Pharma Private Limited - healthcare in Hubli, Karnataka, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹8.23 Cr
▲ 148% YoY
Net profit · FY 2025
₹1 Cr
Net margin 12.2%
EBITDA · FY 2025
₹1.35 Cr
EBITDA margin 16.4%
Authorised capital
₹4 Cr
Registered with MCA
Paid-up capital
₹3.85 Cr
Issued & subscribed
Company age
4 yrs
Est. 2022
Directors on board
2
As per MCA filings
Active GSTINs
1
GST registered
About Endocrine Pharma Private Limited
Data last updated:
Endocrine Pharma Private Limited is a private limited company based in Hubli, Karnataka, India. It operates in the medical and laboratory equipment segment of the healthcare sector. It was incorporated on 12 January 2022.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U24299KA2022PTC156544. Its GSTIN is 29AAGCE8472P1ZP (Karnataka).
The company has an authorised share capital of ₹4 Cr and a paid-up capital of ₹3.85 Cr. It is led by directors Mahantesh Veerappa Gongadashetti and Santosh N Kamath.
Its last annual general meeting (AGM) was held on 22 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Hubli, Karnataka.
As per the financials filed for FY 2025, the company reported a revenue of ₹8.23 Cr, a growth of 148% compared to the previous year. For the same year it recorded a net profit of ₹1 Cr (net margin 12.2%) and EBITDA of ₹1.35 Cr (EBITDA margin 16.4%).
Endocrine Pharma Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-KR-13-0019819). The current compliance status is marked as compliant by the Registrar of Companies.
Company details
CIN U24299KA2022PTC156544
Registration Number 156544
Incorporation Date 12 January 2022
ROC Bangalore
Listing Status Unlisted
Company Status Active
Date of Last AGM 22 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Micro
Udyam Registration UDYAM-KR-13-0019819
Recognitions & Rankings of Endocrine Pharma
Contact details
Endocrine Pharma Private Limited's registered office is in Hubli, Karnataka. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressNo. 03 Survey No 43D/1 Shreya Nagar Behind 1st Gate Vitthal Engineering Works Gokul R, Oad, Hubli, Karnataka, India – 580030
- IndustryHealthcare, Medical & Laboratory Equipment
To see the full contact details of Endocrine Pharma Private Limited, buy the company report.
Comprehensive company report
Endocrine Pharma Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Endocrine Pharma is trade. In detail, this covers retail trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G2 | Retail Trading |
To see the full business activity and turnover split of Endocrine Pharma Private Limited, buy the company report.
Financials of Endocrine Pharma Private Limited
FY 2025 filings availableEndocrine Pharma Private Limited reported revenue of ₹8.23 Cr (up 148% YoY) for FY 2025.
Revenue · FY 2025
₹8.23 Cr ▲ 148%
Net profit · FY 2025
₹1 Cr margin 12.2%
EBITDA · FY 2025
₹1.35 Cr margin 16.4%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 148%
EBITDA CAGR growth
1 year
▲ 132%
3 years · compounded
▲ 731%
Revenue rose 148% in the latest year. EBITDA rose 132% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | ||||
| Other Income | ||||
| Total Revenue | ||||
| Cost of Materials Consumed | ||||
| Employee Benefit Expense | ||||
| Finance Costs | ||||
| Depreciation and Amortisation | ||||
| Other Expenses | ||||
| Total Expenses | ||||
| EBITDA | ₹1.35 Cr | |||
| Profit Before Tax | ||||
| Tax Expense | ||||
| Net Profit (PAT) | ₹1 Cr | |||
| Balance Sheet | ||||
| Share Capital | ||||
| Reserves and Surplus | ||||
| Net Worth (Total Equity) | ||||
| Long-term Borrowings | ||||
| Short-term Borrowings | ||||
| Trade Payables | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | 16.4% | |||
| Net Profit Margin | 12.2% | |||
| Return on Equity (ROE) | ||||
| Return on Capital Employed (ROCE) | ||||
| Return on Assets (ROA) | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Quick Ratio | ||||
| Debt-to-Equity Ratio | ||||
| Interest Coverage Ratio | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Payable Days | ||||
| Inventory Days | ||||
| Revenue Growth | ||||
| Net Profit Growth | ||||
To see the full financial statements and ratios of Endocrine Pharma Private Limited, buy the company report.
Board of directors of Endocrine Pharma Private Limited
Endocrine Pharma has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mahantesh Veerappa Gongadashetti Also directs: Embany Labs LLP | Director | 12 Jul 2022 | 4 Years 3 Months | Current |
| Santosh N Kamath | Director | 12 Jan 2022 | 4 Years 9 Months | Current |
Auditor
Endocrine Pharma Private Limited is audited by YELAMALI ASSOCIATES for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| YELAMALI ASSOCIATES | FY 2024 | AAEPY1020G |
Shareholding
The shareholding of Endocrine Pharma Private Limited is on record for 3 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of Endocrine Pharma Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Endocrine Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Endocrine Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Endocrine Pharma Private Limited has 1 active EPFO establishment as of Mar 30, 2024.
Active EPFO establishments
1
GST
Endocrine Pharma has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAGCE8472P1ZP | Karnataka | Active | 31 Jan 2022 |
To see the full GST registrations and return filing status of Endocrine Pharma Private Limited, buy the company report.
Recent activity
Endocrine Pharma Private Limited has 3 board changes on record since 2022: 2 appointments and 1 cessation. The latest: Mahantesh Veerappa Gongadashetti was appointed as Director on 12 Jul 2022.
AGM
Endocrine Pharma Private Limited last Annual general meeting of members was held on 22 Sep 2025 as per latest MCA records.
Filing
Endocrine Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Bangalore.
Appointed
Mahantesh Veerappa Gongadashetti was appointed as Director.
Ceased
Vinay Madhusudhan Dipali ceased to be Director.
Appointed
Santosh N Kamath was appointed as Director.
Incorporation
12 Jan 2022
Endocrine Pharma Private Limited was registered on 12 Jan 2022 with Roc Bangalore & aged 4 years 9 months as per MCA records.
Frequently asked questions
Endocrine Pharma is an active private limited company based in Hubli, Karnataka, India. The company works in medical and laboratory equipment, within the healthcare industry. It was incorporated on 12 January 2022 (4+ years old) and is registered under CIN U24299KA2022PTC156544.
Endocrine Pharma has 2 current directors:
- Mahantesh Veerappa Gongadashetti - Director
- Santosh N Kamath - Director
The latest financial statements of Endocrine Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 22 September 2025. Year-wise statements from FY 2022 are in the company report.
The GSTIN of Endocrine Pharma is 29AAGCE8472P1ZP, registered in Karnataka.
The CIN (Corporate Identification Number) of Endocrine Pharma is U24299KA2022PTC156544. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Endocrine Pharma was incorporated on 12 January 2022, making it 4+ years old. It is registered with the Registrar of Companies, Bangalore.
Mahantesh Veerappa Gongadashetti was appointed as Director on 12 Jul 2022. Vinay Madhusudhan Dipali ceased to be Director on 12 Jul 2022. Santosh N Kamath was appointed as Director on 12 Jan 2022.
Yes, Endocrine Pharma is registered as a micro enterprise under Udyam registration (number: UDYAM-KR-13-0019819).
The registered office of Endocrine Pharma is at No. 03 Survey No 43D1 Shreya Nagar Behind 1st Gate Vitthal Engineering Works Gokul R, Oad, Hubli, Karnataka, India – 580030.
Endocrine Pharma operates in the healthcare industry, in the medical and laboratory equipment segment.